secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-06-11T12:00:15+00:00
Accession:  0001193125-26-266717
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa raises $4.5M in registered direct offering of stock and warrants
-----------------------------------------------------------------------

- Sold 1,363,638 shares at $3.30/share plus Series A and B warrants for 1,363,638 shares each at $4.40.
- Net proceeds ~$4.1M; expected close June 12, 2026; funds for clinical development and working capital.
- Placement agent gets 7% cash fee plus warrants for 123,000 shares at $4.125.
- Series A warrants expire in 5.5 years, Series B in 2 years; exercise begins 6 months after issuance.
- Potential additional gross proceeds of ~$12M if fully exercised, but no assurance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/0001193125-26-266717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/atos-20260610.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-266717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer